Phillips K A, Fernyak S
School of Pharmacy, University of California, San Francisco, USA.
AIDS. 2000 Sep 29;14(14):2159-69. doi: 10.1097/00002030-200009290-00013.
To estimate the cost-effectiveness of approaches to expanded HIV counselling and testing.
A cost-effectiveness analysis.
Primary care practices in the USA.
New patient visits.
Two approaches were examined: (i) requesting all patients to complete an HIV-risk screening instrument, with counselling as well as testing offered only to patients disclosing risk factors ('risk histories' option); and (ii) routine offering of voluntary testing to all patients, with consent obtained but no pre-test counselling ('routine testing').
The primary outcome was the cost per infection identified. We also examined: (i) the costs and numbers of infections averted if individuals change their risk behaviours; and (ii) the additional years of life and quality-adjusted life years (QALY) gained as a result of earlier HIV testing and treatment for infected individuals.
Routine testing is the most cost-effective approach to identifying infected individuals at an incremental cost of US$4200 per infection identified. Although using risk histories is more costly and less effective than routine testing, it becomes similarly cost-effective using plausible ranges for sensitivity analyses. If at least 10% of HIV-positive individuals change their behavior, both routine testing and using risk histories would save money. If testing identifies infected individuals one year earlier than they otherwise would have been diagnosed, routine testing would cost US$22000 per QALY gained.
Routine testing is the most cost-effective approach to identifying new HIV infections. However, using risk histories may be similarly cost-effective under various assumptions. Both routine testing and using risk histories are more cost-effective than current practices.
评估扩大艾滋病毒咨询与检测方法的成本效益。
成本效益分析。
美国的基层医疗诊所。
新患者就诊。
研究了两种方法:(i)要求所有患者完成艾滋病毒风险筛查工具,仅向披露风险因素的患者提供咨询和检测(“风险史”选项);(ii)向所有患者常规提供自愿检测,获得同意但不进行检测前咨询(“常规检测”)。
主要结局是每发现一例感染的成本。我们还研究了:(i)如果个体改变其风险行为,避免的感染成本和数量;(ii)由于对感染者进行更早的艾滋病毒检测和治疗而获得的额外生命年和质量调整生命年(QALY)。
常规检测是发现感染者最具成本效益的方法,每发现一例感染的增量成本为4200美元。尽管使用风险史比常规检测成本更高且效果更差,但在敏感性分析的合理范围内,它具有类似的成本效益。如果至少10%的艾滋病毒阳性个体改变其行为,常规检测和使用风险史都将节省资金。如果检测比原本诊断时间提前一年发现感染者,常规检测每获得一个QALY的成本为22000美元。
常规检测是发现新的艾滋病毒感染最具成本效益的方法。然而,在各种假设下,使用风险史可能具有类似的成本效益。常规检测和使用风险史都比现行做法更具成本效益。